Abstract
No public abstract is available from the verified source records.
Heiner Wedemeyer
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
10.1136/gutjnl-2020-323888 · 2021
Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load
10.1016/j.jhep.2021.04.051 · 2021
Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion
2024
Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles
10.1128/jvi.00430-14 · 2014
Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss
10.1136/gutjnl-2023-330577 · 2024
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta
10.1002/hep.27102 · 2014
Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta
10.1111/jvh.13366 · 2020
Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy
10.1002/ueg2.70153 · 2026
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
2025
EASL Clinical Practice Guidelines on hepatitis delta virus
10.1016/j.jhep.2023.05.001 · 2023
Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation
10.1016/j.jhep.2011.06.016 · 2012
Virological and clinical characteristics of delta hepatitis in Central Europe
10.1111/j.1365-2893.2009.01144.x · 2009
Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes
10.1002/hep.31214 · 2020
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis
10.1016/j.jhep.2020.04.008 · 2020
High Rates of Advanced Chronic Liver Disease in Patients With Chronic Hepatitis D Virus Infection in Uzbekistan
10.1111/liv.70799 · 2026
Double reflex testing for anti-HDV antibody following an HBsAg-positive test result and HDV RNA in those anti-HDV positive: a global systematic review and meta-analysis
10.1016/j.eclinm.2025.103708 · 2026
Diabetes, male sex, low levels of HBsAg, HDV RNA, and ALT predict spontaneous HDV suppression in chronic hepatitis D
10.1097/hep.0000000000001786 · 2026
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial
10.1016/j.jhep.2026.03.046 · 2026
Unresolved referenced work
Kept as external metadata until matched
Increase in HDV replication during steroid therapy - potential implications for testing and treatment strategies
10.1016/j.jhep.2023.11.019 · 2024
Immunology of hepatitis D virus infection: General concepts and present evidence
10.1111/liv.15424 · 2023
Unresolved referenced work
Kept as external metadata until matched
Serum HBsAg cannot distinguish cccDNA activity from integrated HBV DNA expression in chronic hepatitis B virus infection
2026
Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024
10.1111/liv.70189 · 2025
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis
10.1016/j.jhep.2024.12.044 · 2025
Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies
10.1016/j.jhep.2024.01.035 · 2024
No additional external references are available.